Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore
New Delhi: US-based Private investment firm Bain Capital has pared down its stake in Emcure Pharmaceuticals, offloading a 2.4 percent holding in the company for Rs 563 crore through an open market transaction.
Following the sale, Bain Capital’s shareholding in Emcure dropped from 8.68 percent to 6.31 percent, PTI reported.
According to bulk deal data from the National Stock Exchange (NSE), Bain Capital, acting through its BC Investments IV, sold 45 lakh shares of Emcure Pharmaceuticals at an average price of Rs 1,250.44 apiece. The total transaction value stood at Rs 562.7 crore.
Details of the buyers of Emcure Pharmaceuticals' shares could not be ascertained on the exchange.
Additionally, in April 2025, Tillomed Laboratories Limited, a subsidiary of Emcure Pharma and a European pharma company, entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries Manx Pharma Ltd and Manx Generics Limited.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.